Davide Massano

The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients

A. Piga, F. Longo, A. de Nicolò, 2019, The Pharmacogenomics Journal.

Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients

A. Piga, F. Longo, A. de Nicolò, 2018, Pharmacogenetics and genomics.

Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes

A. Piga, F. Longo, A. de Nicolò, 2017, The Pharmacogenomics Journal.

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.

A. Piga, F. Longo, A. D’Avolio, 2017, Pharmacogenomics.

Role of pharmacogenetics on deferasirox AUC and efficacy.

A. Piga, A. D’Avolio, J. Cusato, 2016, Pharmacogenomics.

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children

A. Piga, F. Longo, A. D’Avolio, 2018, Pharmacogenetics and genomics.

Clinical relevance of deferasirox trough levels in β‐thalassemia patients

A. Piga, F. Longo, A. D’Avolio, 2018, Clinical and experimental pharmacology & physiology.